Loading...
XSHE
002022
Market cap464mUSD
Oct 09, Last price  
6.20CNY
1D
2.48%
1Q
27.31%
Jan 2017
-69.00%
IPO
296.17%
Name

Shanghai Kehua Bio-Engineering Co Ltd

Chart & performance

D1W1MN
XSHE:002022 chart
P/E
—
P/S
1.94
EPS
—
Div yield, %
—
Shrs. gr., 5y
-0.66%
Rev. gr., 5y
-19.49%
Revenues
1.64b
-6.63%
399,096,017487,116,254621,196,340781,315,791873,890,4421,013,681,3211,114,434,6311,217,885,7321,155,783,3431,396,672,0881,594,116,2111,990,213,5572,414,471,2894,155,428,8464,854,310,5234,854,310,5236,969,862,6272,428,075,2131,759,197,3291,642,485,860
Net income
-732m
L+14.29%
117,997,267166,075,707204,342,546225,258,510226,748,967239,830,025288,329,178291,973,953210,624,937232,400,489217,759,953207,778,852202,475,424675,356,4201,353,824,760850,413,416971,562,252-234,014,888-640,601,876-732,140,993
CFO
22m
P
87,211,768112,932,259137,662,631217,508,063241,827,895219,800,208213,743,675250,221,961249,638,498224,298,097281,252,696130,713,194126,790,596248,872,0341,367,198,2501,079,220,2642,153,632,187-474,894,786-50,115,99922,438,665
Dividend
May 10, 20230.6 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Shanghai Kehua Bio-Engineering Co.,Ltd, together with its subsidiaries, engages in the research, development, production, and sale of in vitro diagnostic reagents and medical testing equipment and services in China and internationally. The company offers immunoassay and clinical chemistry systems, HIV colloid gold test kits, ELISA HBV test kits, renal disease management solution, and automated comprehensive solutions for nucleic acid blood screening. It also provides automatic modular and clinical chemistry analyzers and clinical chemistry reagents test menu; automatic chemiluminescence immunoassay analyzers and CLIA reagents test menu; automatic ELISA microplate readers, ELISA microplate washers, and enzyme-linked immunoassay reagents; and diagnostics kit for HIV and SARS-CoV-2 IgM/IgG antibody, HIV I/II Ab rapid tests, diagnostic kit for Hepatitis B surface antigen and Hepatitis C virus antibody, and diagnostic kit for antibody to T. Palladium. In addition, the company offers molecular diagnostics solutions, including fully automated nucleic acid blood screening laboratory solution and nucleic acid testing and detection kits; automatic multifunctional veterinary analyzer; and mass spectrometry. It exports its products. The company serves healthcare institutions, blood centers, disease control and prevention centers, and research organizations. Its products are used in clinical diagnostics, blood screening, public health, food safety, and scientific research applications. The company was founded in 1981 and is headquartered in Shanghai, China.

Key people

Ming Li
Chairman of the Board, President · since 2024
Zhichao Ma
Vice Chairman of the Board · since 2024
Fang Luo
Chief Financial Officer · since 2016
Hyuk Shin Kang
Vice President · since 2023
Baogang Miao
Vice President, Director · since 2024
Hongying Jin
Vice President, Secretary of the Board, Director · since 2023
Jiaming Liang
Vice President, Director · since 2024
Niancai Peng
Director · since 2024
Chao Yi
Staff Elected Director · since 2025
Wenhua Shan
Independent Director · since 2024
Zhenxi Zhang
Independent Director · since 2024
Chuanfang Zheng
Independent Director · since 2023
IPO date
Jul 21, 2004
Employees
Domiciled in
CN
Incorporated in
CN
Headquarters & legal address
上海市徐汇区钦州北路1189号
徐汇区, SH 200000
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122022‑002021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT